US5446177A
(en)
*
|
1984-12-28 |
1995-08-29 |
Alcon Laboratories, Inc. |
Anti-inflammatory compounds for ophthalmic use
|
US4686214A
(en)
*
|
1985-10-30 |
1987-08-11 |
Alcon Laboratories, Inc. |
Anti-inflammatory compounds for ophthalmic use
|
US4914090A
(en)
*
|
1985-11-01 |
1990-04-03 |
Schering Corporation |
Ophthalmic compositions
|
IL79661A
(en)
*
|
1986-08-08 |
1991-01-31 |
Yeda Res & Dev |
Antiviral composition containing hypericin or pseudohypericin
|
US4808610A
(en)
*
|
1986-10-02 |
1989-02-28 |
Schering Corporation |
Mometasone furoate anti-inflammatory cream composition using hexylene glycol
|
US4775529A
(en)
*
|
1987-05-21 |
1988-10-04 |
Schering Corporation |
Steroid lotion
|
US6536427B2
(en)
|
1990-03-02 |
2003-03-25 |
Glaxo Group Limited |
Inhalation device
|
MY105368A
(en)
*
|
1990-03-02 |
1994-09-30 |
Glaxo Group Ltd |
Inhalation device.
|
SK280968B6
(sk)
|
1990-03-02 |
2000-10-09 |
Glaxo Group Limited |
Balenie medikamentu na použite v inhalačnom prístroji
|
AU663471B2
(en)
|
1990-09-10 |
1995-10-12 |
Merck Sharp & Dohme Corp. |
Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
|
EP0587790B2
(en)
|
1991-06-10 |
2000-03-08 |
Schering Corporation |
Non-chlorofluorocarbon aerosol formulations
|
ES2158910T3
(es)
†
|
1991-06-10 |
2001-09-16 |
Schering Corp |
Formulaciones en aerosol sin clorofluorocarbonos.
|
US6127353A
(en)
*
|
1991-09-06 |
2000-10-03 |
Schering Corporation |
Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
|
US5420120A
(en)
*
|
1993-12-17 |
1995-05-30 |
Alcon Laboratories, Inc. |
Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
|
AU701833B2
(en)
*
|
1993-12-21 |
1999-02-04 |
Merck Sharp & Dohme Corp. |
Psoriasis treatment
|
US5837699A
(en)
*
|
1994-01-27 |
1998-11-17 |
Schering Corporation |
Use of mometasone furoate for treating upper airway passage diseases
|
PE44995A1
(es)
|
1994-01-27 |
1995-12-18 |
Schering Corp |
Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
|
US5502076A
(en)
*
|
1994-03-08 |
1996-03-26 |
Hoffmann-La Roche Inc. |
Dispersing agents for use with hydrofluoroalkane propellants
|
DE4433374A1
(de)
*
|
1994-09-20 |
1996-03-21 |
Hoechst Ag |
17-Desoxi-corticosteroid-21-/O/-Carbonsäure- ester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
|
US5696105A
(en)
*
|
1996-03-14 |
1997-12-09 |
Hackler; Walter A. |
Antifungal nail composition
|
KR100441187B1
(ko)
*
|
1996-06-28 |
2004-11-03 |
쉐링 코포레이션 |
9α,21-디할로-프레그난-11β,17α-디올-20-온의17-에스테르의제조방법
|
US5886200A
(en)
*
|
1996-07-01 |
1999-03-23 |
Schering Corporation |
Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
|
US6495167B2
(en)
|
1997-03-20 |
2002-12-17 |
Schering Corporation |
Preparation of powder agglomerates
|
US6503537B2
(en)
|
1997-03-20 |
2003-01-07 |
Schering Corporation |
Preparation of powder agglomerates
|
US6297227B1
(en)
|
1998-09-10 |
2001-10-02 |
Schering Corporation |
Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
|
US8722668B2
(en)
*
|
1998-12-23 |
2014-05-13 |
Daryl W. Hochman |
Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
|
PT102343B
(pt)
|
1999-08-02 |
2003-11-28 |
Hovione Farmaciencia Sa |
Processo para a preparacao de furoato mometasona
|
PT102405A
(pt)
*
|
2000-01-20 |
2001-07-31 |
Hovione Farmaciencia Sa |
Processo para a preparacao de mometasona
|
GB0009609D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Therapeutic compositions
|
GB0009605D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Medicaments
|
GB0009612D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Therapeutic formulations
|
GB0015876D0
(en)
*
|
2000-06-28 |
2000-08-23 |
Novartis Ag |
Organic compounds
|
US20020076382A1
(en)
*
|
2000-08-04 |
2002-06-20 |
Kaplan Leonard W. |
Formulations of mometasone and a bronchodilator for pulmonary administration
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
AR032471A1
(es)
*
|
2000-08-05 |
2003-11-12 |
Glaxo Group Ltd |
Derivado de androstano y solvatos del mismo, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que los comprenden, procesos para preparar tales derivados, intermediarios utiles en la preparacion de tales derivados, procesos para preparar tales intermediarios, y compuestos inter
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6858596B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivative
|
GB0019172D0
(en)
*
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
CA2445839A1
(en)
|
2001-04-30 |
2002-11-07 |
Glaxo Group Limited |
Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
|
US20040248867A1
(en)
*
|
2001-06-12 |
2004-12-09 |
Keith Biggadike |
Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
|
GB0125259D0
(en)
|
2001-10-20 |
2001-12-12 |
Glaxo Group Ltd |
Novel compounds
|
GB0127160D0
(en)
*
|
2001-11-12 |
2002-01-02 |
Glaxo Group Ltd |
Novel compounds
|
WO2003042229A1
(en)
*
|
2001-11-12 |
2003-05-22 |
Glaxo Group Limited |
Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
|
ITMI20020148A1
(it)
*
|
2002-01-29 |
2003-07-29 |
Nicox Sa |
Nuovi corticosteroidi
|
US20050175545A1
(en)
*
|
2002-02-04 |
2005-08-11 |
Keith Biggadike |
Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
|
GB0202635D0
(en)
*
|
2002-02-05 |
2002-03-20 |
Glaxo Wellcome Mfg Pte Ltd |
Formulation containing novel anti-inflammatory androstane derivative
|
GB0207906D0
(en)
|
2002-04-05 |
2002-05-15 |
3M Innovative Properties Co |
Formoterol and mometasone aerosol formulations
|
GB2389530B
(en)
|
2002-06-14 |
2007-01-10 |
Cipla Ltd |
Pharmaceutical compositions
|
MXPA05011225A
(es)
*
|
2003-04-18 |
2005-12-14 |
Pharmacia & Upjohn Co Llc |
Politerapias.
|
EP1663999A2
(en)
*
|
2003-08-29 |
2006-06-07 |
Ranbaxy Laboratories, Ltd. |
Inhibitors of phosphodiesterase type-iv
|
WO2005051931A2
(en)
*
|
2003-11-26 |
2005-06-09 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
PL1711164T3
(pl)
|
2004-01-21 |
2010-09-30 |
Merck Sharp & Dohme |
Sposób leczenia ostrego zapalenia zatok przynosowych
|
US20080009535A1
(en)
*
|
2004-08-30 |
2008-01-10 |
Sarala Balachandran |
Inhibitors of phosphodiesterase type-IV
|
US20060211667A1
(en)
*
|
2005-03-21 |
2006-09-21 |
Eric Marchewitz |
Use of pregnane steroid derivatives for enhancing physical performance
|
GB0507165D0
(en)
*
|
2005-04-08 |
2005-05-18 |
Glaxo Group Ltd |
Novel crystalline pharmaceutical product
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
GB0523653D0
(en)
*
|
2005-11-21 |
2005-12-28 |
Novartis Ag |
Organic compounds
|
US20070099883A1
(en)
*
|
2005-10-07 |
2007-05-03 |
Cheryl Lynn Calis |
Anhydrous mometasone furoate formulation
|
AU2006305620A1
(en)
*
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
CA2626612A1
(en)
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of muscarinic receptor antagonists
|
CN100436473C
(zh)
*
|
2005-12-09 |
2008-11-26 |
天津药业集团有限公司 |
糠酸莫美他松中间体21-酯及制法
|
CN100389121C
(zh)
*
|
2005-12-09 |
2008-05-21 |
天津药业集团有限公司 |
糠酸莫美他松中间体21-羟的制备方法
|
TWI374147B
(en)
*
|
2006-01-27 |
2012-10-11 |
Sun Pharma Advance Res Company Ltd |
Novel 11β-hydroxyandrosta-4-ene-3-ones
|
GB0615108D0
(en)
*
|
2006-07-28 |
2006-09-06 |
Glaxo Group Ltd |
Novel formulations
|
CN101616901A
(zh)
*
|
2006-09-22 |
2009-12-30 |
兰贝克赛实验室有限公司 |
Iv型磷酸二酯酶的抑制剂
|
EP2066661A2
(en)
*
|
2006-09-22 |
2009-06-10 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
US20090325917A1
(en)
*
|
2006-10-19 |
2009-12-31 |
Cipla Limited |
Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate
|
US20080207659A1
(en)
*
|
2007-02-15 |
2008-08-28 |
Asit Kumar Chakraborti |
Inhibitors of phosphodiesterase type 4
|
CN103497185A
(zh)
|
2007-03-14 |
2014-01-08 |
兰贝克赛实验室有限公司 |
用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
|
US20110130403A1
(en)
*
|
2007-03-14 |
2011-06-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
|
EP2120868A4
(en)
*
|
2007-04-11 |
2010-08-25 |
Perrigo Israel Phamaceuticals |
LOW-DOSED MOMETASON FORMULATIONS
|
WO2009063493A2
(en)
*
|
2007-09-10 |
2009-05-22 |
Glenmark Pharmaceuticals Limited |
Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid
|
US20090082318A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched mometasone
|
US8796248B2
(en)
*
|
2007-10-05 |
2014-08-05 |
Nektar Therapeutics |
Oligomer-corticosteroid conjugates
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
HUE046243T2
(hu)
|
2008-05-28 |
2020-02-28 |
Reveragen Biopharma Inc |
Nem-hormonális NF-KB szteroid modulátorok betegség kezelésére
|
UY32297A
(es)
|
2008-12-22 |
2010-05-31 |
Almirall Sa |
Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
|
EP2228368A1
(en)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
|
ES2774391T3
(es)
*
|
2009-05-29 |
2020-07-20 |
Pearl Therapeutics Inc |
Composiciones, métodos y sistemas para la administración respiratoria de dos o más agentes activos
|
US8815258B2
(en)
|
2009-05-29 |
2014-08-26 |
Pearl Therapeutics, Inc. |
Compositions, methods and systems for respiratory delivery of two or more active agents
|
KR20120104975A
(ko)
|
2009-10-01 |
2012-09-24 |
앱탈리스 파마테크, 인코포레이티드 |
경구 투여용 코르티코스테로이드 조성물
|
WO2011093810A2
(en)
|
2010-01-28 |
2011-08-04 |
Bilgic Mahmut |
Dry powder pharmaceutical composition comprising tiotropium and mometasone
|
WO2011093815A2
(en)
|
2010-01-29 |
2011-08-04 |
Mahmut Bilgic |
Pharmaceutical compositions comprising formoterol and mometasone
|
EP2556083A4
(en)
|
2010-04-05 |
2013-12-04 |
Validus Biopharma Inc |
NONHORMONAL STEROID MODULATORS OF NF-KAPPA-B FOR DISEASE TREATMENT
|
WO2011136754A1
(en)
|
2010-04-26 |
2011-11-03 |
Mahmut Bilgic |
A medicament developed for the treatment of respiratory diseases
|
JOP20120023B1
(ar)
|
2011-02-04 |
2022-03-14 |
Novartis Ag |
صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
|
EP2578570A1
(en)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
|
WO2013109207A1
(en)
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Dry powder formulations comprising mometasone
|
EP2641900A1
(en)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
|
WO2014007771A2
(en)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Inhalation compositions comprising muscarinic receptor antagonist
|
US20150224197A1
(en)
|
2012-07-05 |
2015-08-13 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Inhalation compositions
|
WO2014007772A2
(en)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Inhalation compositions comprising glucose anhydrous
|
US20150165037A1
(en)
|
2012-07-05 |
2015-06-18 |
Arven llac Sanayi Ve Ticaret A.S. |
Inhalation compositions comprising corticosteroid and sorbitol
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
CA2898700C
(en)
|
2013-03-14 |
2022-07-19 |
Novartis Ag |
Deamorphization of spray-dried formulations via spray-blending
|
RU2696582C2
(ru)
|
2013-03-15 |
2019-08-05 |
Перл Терапьютикс, Инк. |
Способы и системы кондиционирования дисперсных кристаллических материалов
|
MX2015016058A
(es)
|
2013-05-22 |
2016-12-20 |
Pearl Therapeutics Inc |
Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos.
|
WO2015034678A2
(en)
|
2013-09-06 |
2015-03-12 |
Aptalis Pharmatech, Inc. |
Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
|
WO2015145353A1
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
|
EP3006453A1
(en)
|
2014-10-08 |
2016-04-13 |
Cosmo Technologies Ltd. |
17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
|
WO2017004205A1
(en)
|
2015-06-29 |
2017-01-05 |
Reveragen Biopharma, Inc. |
NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
|
CN105481933B
(zh)
*
|
2015-12-25 |
2017-09-19 |
山东京卫制药有限公司 |
一种合成糠酸莫米松的方法
|
CN107266519B
(zh)
*
|
2016-04-08 |
2021-06-29 |
天津金耀集团有限公司 |
一种9β,11β-环氧-17α-羟基-16α-甲基-21-氯代-1,4孕甾二烯-3,20-二酮新晶型及其制备方法
|
CN107266518B
(zh)
*
|
2016-04-08 |
2021-03-30 |
天津金耀集团有限公司 |
一种糠酸莫米松晶型及其制备方法
|
TWI777515B
(zh)
|
2016-08-18 |
2022-09-11 |
美商愛戴爾製藥股份有限公司 |
治療嗜伊紅性食道炎之方法
|
CN107793462A
(zh)
*
|
2016-08-30 |
2018-03-13 |
天津太平洋制药有限公司 |
一种丙酸氯倍他索的制备方法
|
CN107778341A
(zh)
*
|
2016-08-30 |
2018-03-09 |
天津太平洋制药有限公司 |
一种哈西奈德的制备方法
|
CN109206468B
(zh)
*
|
2017-06-30 |
2023-06-27 |
天津药业研究院股份有限公司 |
一种糠酸莫米松的制备方法
|
CN109206466B
(zh)
*
|
2017-06-30 |
2022-08-09 |
天津药业研究院股份有限公司 |
一种甾体21位羟基氯代或溴代方法
|
CN107573398B
(zh)
*
|
2017-09-07 |
2021-02-26 |
山东泰华生物科技股份有限公司 |
一种哈西奈德及其衍生物的制备方法
|
CN108395465B
(zh)
*
|
2018-05-10 |
2019-07-30 |
浙江仙居仙乐药业有限公司 |
一种地塞米松环氧水解物的合成方法
|
US11382922B2
(en)
|
2019-03-07 |
2022-07-12 |
Reveragen Biopharma, Inc. |
Aqueous oral pharmaceutical suspension compositions
|
IL309888A
(en)
|
2021-07-09 |
2024-03-01 |
Astrazeneca Pharmaceuticals Lp |
Aerosol drug delivery compounds, methods and systems
|
WO2023119093A1
(en)
|
2021-12-20 |
2023-06-29 |
Astrazeneca Ab |
Compositions, methods and systems for aerosol drug delivery
|